The EU has approved Gilead’s TROP2-directed ADC Trodelvy (sacituzumab govitecan) as monotherapy for first-line unresectable or metastatic triple-negative breast cancer in patients who cannot receive PD-(L)1 inhibitors, backed by the Phase III ASCENT-03 study. In ASCENT-03, Trodelvy cut the risk of progression or death by 38% versus chemotherapy, with median progression-free survival of 9.7 months vs. 6.9 months.

Why It Matters To Oncology

• Trodelvy becomes the first ADC approved in Europe for previously untreated metastatic TNBC.

• The label addresses a high-need frontline population that is ineligible for PD-(L)1 blockade, where Gilead says no new treatment option has emerged in roughly two decades.

• For clinicians and drug developers, the decision further validates TROP2 as a frontline target in TNBC and strengthens the ADC playbook in breast cancer.

The Financials

• The approval expands Trodelvy’s commercial reach in Europe into an earlier-line TNBC setting, potentially broadening use beyond later-line disease.

• Competitive pressure is building: AstraZeneca and Daiichi Sankyo’s Datroway is under EU review for a similar first-line TNBC population after a recent US label expansion.

• The move also raises the strategic value of lifecycle expansion, with Trodelvy plus Merck’s Keytruda under EMA review for PD-L1–positive unresectable locally advanced or metastatic TNBC.

What They're Saying

• Gilead oncology head Mika Kakefuda Derynck called the approval “a significant step forward” in treating first-line metastatic TNBC in Europe.

• She added that the EU decision will provide “a much-needed new option” for eligible patients.

• Gilead said that, if the combination label is approved, Trodelvy could become a backbone treatment in first-line metastatic TNBC across PD-L1 status in Europe.

What's Next

• Watch the EU review of Datroway, the next TROP2 ADC contender in frontline TNBC.

• Also watch the EMA decision on Trodelvy plus pembrolizumab in PD-L1–positive disease, based on the Phase III ASCENT-04 study.

• In the US, Trodelvy monotherapy remains under review for frontline unresectable locally advanced or metastatic TNBC, alongside filings for pembrolizumab-based combinations.